Report on Manufacturer of Opioids Fee Assessments as Required by Public Law 2020 Chapter 536 (LD793)
Bureau/Division/Agency
Professional and Financial Regulation
Document Type
Text
Exact Creation Date
10-1-2024
Language
English
Recommended Citation
Department of Professional and Financial Regulation, "Report on Manufacturer of Opioids Fee Assessments as Required by Public Law 2020 Chapter 536 (LD793)" (2024). PFR Office of the Commissioner - Reports and Sunrise Reviews. 45.
https://digitalmaine.com/pfr_docs/45
File Size
167 KB
Files over 3MB may be slow to open. For best results, right-click and select "Save As"
Rights Statement
No Copyright - United States. URI: http://rightsstatements.org/vocab/NoC-US/1.0/
The organization that has made the Item available believes that the Item is in the Public Domain under the laws of the United States, but a determination was not made as to its copyright status under the copyright laws of other countries. The Item may not be in the Public Domain under the laws of other countries. Please refer to the organization that has made the Item available for more information.
Description
The Board of Pharmacy is required pursuant to Public Law 2020 Chapter 536 to collect a $55,000.00 fee from each opioid medication manufacturer, less $325.00 which may be retained by the Board of Pharmacy and $250,000.00 product registration fee assessment from manufacturers that sell, deliver, or distribute 2,000,000 or more units of an opioid medication within Maine. This fee does not apply to a manufacturer of an opioid medication if all of that manufacturer’s opioid medications are approved by the United States Food andDrug Administration for use only in veterinary medicine.